Core Insights - BioMarin Pharmaceutical missed both revenue and earnings estimates in the third quarter, indicating potential challenges in financial performance [1] Financial Performance - The company reported lower than expected revenue and earnings for the third quarter [1] - Despite the earnings miss, shares of BioMarin are up 1% in after-hours trading, suggesting a possible positive market reaction or investor sentiment [1]

BioMarin Pharmaceutical (BMRN) reported $776.13 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.1%. EPS of $0.12 for the same period compares to $0.91 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $784.4 million, representing a surprise of -1.05%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Core Viewpoint - BioMarin Pharmaceutical plans to divest its gene therapy product, which was once anticipated to be a blockbuster treatment for a rare bleeding disorder [1] Company Summary - The gene therapy in question was previously expected to generate significant revenue as a leading treatment option for a specific rare bleeding disorder [1]

Core Insights - BioMarin Pharmaceutical reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of a loss of $0.15 per share, but down from $0.91 per share a year ago [1] - The earnings surprise was +180.00%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenue for the quarter was $776.13 million, slightly missing the Zacks Consensus Estimate by 1.05%, but up from $745.74 million year-over-year [3] Earnings Performance - The company has consistently exceeded consensus EPS estimates, achieving this in four consecutive quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.97, with expected revenues of $819.69 million, and for the current fiscal year, the EPS estimate is $3.54 on revenues of $3.18 billion [8] Stock Performance and Outlook - BioMarin shares have declined approximately 17.1% year-to-date, contrasting with the S&P 500's gain of 15.5% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Industry Context - The Medical - Biomedical and Genetics industry, to which BioMarin belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The performance of BioMarin's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [6][9]

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q3 2025 Earnings Call October 27, 2025 04:30 PM ET Company ParticipantsZaki Molvi - Senior Associate of Biotechnology Equity ResearchJulian Pino - Senior Associate of Biotechnology Equity ResearchTraci McCarty - Head of Investor RelationsAlexander Hardy - President and CEOCristin Hubbard - Chief Commercial OfficerChris Raymond - Managing DirectorBrian Mueller - CFOGreg Friberg - Chief Research and Development OfficerConference Call ParticipantsSalveen Richter - Biotec ...

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q3 2025 Earnings Call October 27, 2025 04:30 PM ET Company ParticipantsZaki Molvi - Senior Associate of Biotechnology Equity ResearchJulian Pino - Senior Associate of Biotechnology Equity ResearchTraci McCarty - Head of Investor RelationsAlexander Hardy - President and CEOCristin Hubbard - Chief Commercial OfficerChris Raymond - Managing DirectorBrian Mueller - CFOGreg Friberg - Chief Research and Development OfficerConference Call ParticipantsSalveen Richter - Biotec ...

Financial Data and Key Metrics Changes - BioMarin reported an 11% year-over-year increase in total revenue, with cash and investments reaching approximately $2 billion at the end of Q3 2025 [5][6][15] - The company raised its full-year 2025 total revenue guidance to a range of $3.15 billion, reflecting strong performance and operational efficiencies [12][15] - Non-GAAP diluted earnings per share guidance was updated to between $3.50 and $3.60, with an operating margin guidance of 26% to 27% [15][17] Business Line Data and Key Metrics Changes - The Enzyme Therapies business unit experienced 8% year-to-date growth, with Palynziq and VoxoGo each increasing by over 20% year-to-date [12][19] - VoxoGo revenue is expected to reach between $900 million and $935 million for the full year 2025, with a 24% increase year-to-date compared to 2024 [6][12][20] - The Skeletal Conditions business unit, driven by FOXOGO, is projected to generate over $900 million in revenue for 2025, representing a 25% growth at the midpoint of guidance [6][19] Market Data and Key Metrics Changes - Approximately 75% of year-to-date VoxoGo revenue was generated outside the U.S., indicating strong international demand [20][21] - VoxoGo is now available in 55 countries, with significant growth in patient numbers quarter-over-quarter [20][21] Company Strategy and Development Direction - BioMarin is focusing on strategic investments in the Enzyme Therapies and Skeletal Conditions business units while pursuing options to divest ROCTAVIAN [9][10] - The company aims to expand its global footprint and deepen penetration in existing markets, particularly for VoxoGo and upcoming indications [20][21] - Future growth is anticipated through new product launches and business development opportunities, with a focus on advancing internal pipelines [11][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record commercial results for the full year, despite challenges from potential competition [5][11] - The company is monitoring various market dynamics and has developed multiple scenarios for future revenue, particularly concerning VoxoGo competition [17][42] - Management emphasized the importance of maintaining value-creating activities while pursuing operational efficiencies [75] Other Important Information - A charge of $221 million for acquired in-process research and development related to the Enizyme Pharma acquisition impacted Q3 results [14] - The company is preparing for pivotal data readouts and potential new approvals in the coming quarters, particularly for hypochondroplasia and BMN 333 [36][37] Q&A Session Summary Question: Can you elaborate on the 2027 guidance and the changes since it was initially issued? - Management indicated that various factors, including potential VoxoGo competition and the acquisition of Inozyme, influenced the revised outlook, leading to a range of estimates rather than a specific forecast [39][42] Question: Why were VoxoGo sales down quarter-over-quarter? - Management noted that the decline was due to timing shifts in larger orders and reaffirmed the total revenue range for VoxoGo for the year [48][50] Question: What is the company's strategy for business development? - Management highlighted a focus on early-stage collaborations and Phase III assets, emphasizing that business development remains a high priority [52][54] Question: What are the expectations for the upcoming BMN 333 data? - Management stated that they are looking for significant increases in free CNP levels to demonstrate clinical superiority over VoxoGo [64][66] Question: Can you clarify the 2027 cash flow targets? - Management confirmed that the cash flow targets are tied to revenue scenarios and emphasized ongoing optimization initiatives [79][80]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Third Quarter 2025 Earnings October 27, 2025 Forward-Looking Statements This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations of Total Revenues, Non-GAAP Operating Margin percentage, Non-GAAP Diluted EPS and Operating Cash Flow for, in certain instances, the full-year 2025 and future pe ...

Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO BioMarin Focuses Commercial Portfolio; Pursuing Options to Divest ROCTAV ...